Answers are grounded in this paper and cite their sources.
We reviewed our experience in the treatment of stages I and II nonseminomatous testicular tumors to evaluate new trends and improvements in this disease. Of the patients with stage I disease there was a significantly higher percentage of survivors among those who received adjunctive chemotherapy with actinomycin D. Since these patients were not randomized prospectively this observation should be taken only as a suggestion of the possible effectiveness of adjunctive chemotherapy in this group. However, the greatest advances have been observed among patients with stage IIB disease. Since the establishment of modern accepted combination chemotherapy survival free of disease (minimal followup 2 years) in this group has tripled.
No takes yet. Share an insight, caveat, or question.
Pontes et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: